

Are cysteine-rich and COOH-terminal domains of dystrophin critical for sarcolemmal localization?

D Récan, ... , P Czernichow, L V Nicholson

J Clin Invest. 1992;89(2):712-716. <https://doi.org/10.1172/JCI115640>.

Research Article

It has been hypothesized that the tight localization of dystrophin at the muscle membrane is carried out by its cysteine-rich and/or carboxyl domains. We report the results of biochemical and immunocytochemical investigations of dystrophin in muscle from a 1-yr-old patient with a large deletion that removes the distal part of the dystrophin gene, thus spanning the exons coding for the cysteine-rich and the carboxy-terminal domains, and extends beyond the glycerol kinase and congenital adrenal hypoplasia genes. Immunological analysis of muscle dystrophin shows that the deletion results in the production of a truncated, but stable, polypeptide correctly localized at the sarcolemma. These data indicate that neither the cysteine-rich domain, nor the carboxyl domain, are necessary for the appearance of normal dystrophin sarcolemmal localization.

Find the latest version:

<https://jci.me/115640/pdf>



Are Cysteine-rich and COOH-Terminal Domains of Dystrophin Critical for Sarcolemmal Localization?

Dominique Récan,* Philippe Chafey,* France Leturcq,* Jean-Philippe Hugnot,* Nathalie Vincent,* Fernando Tomé,† Huguette Collin,‡ Dominique Simon,§ Paul Czernichow,§ Louise V. B. Nicholson,|| Michel Fardeau,‡ Jean-Claude Kaplan,* and Jamel Chelly*

*Institut National de la Santé et de la Recherche Médicale (INSERM) U129, Institut Cochin de Génétique Moléculaire, 75014 Paris, France; †INSERM U153, 75005 Paris, France; ‡Service de Pédiatrie, Hôpital Robert Debré, 75019 Paris, France; §Muscular Dystrophy Research Laboratories, Newcastle General Hospital, Newcastle upon Tyne NE46BE, United Kingdom

Abstract

It has been hypothesized that the tight localization of dystrophin at the muscle membrane is carried out by its cysteine-rich and/or carboxyl domains. We report the results of biochemical and immunocytochemical investigations of dystrophin in muscle from a 1-yr-old patient with a large deletion that removes the distal part of the dystrophin gene, thus spanning the exons coding for the cysteine-rich and the carboxy-terminal domains, and extends beyond the glycerol kinase and congenital adrenal hypoplasia genes. Immunological analysis of muscle dystrophin shows that the deletion results in the production of a truncated, but stable, polypeptide correctly localized at the sarcolemma. These data indicate that neither the cysteine-rich domain, nor the carboxyl domain, are necessary for the appearance of normal dystrophin sarcolemmal localization. (*J. Clin. Invest.* 1992, 89:712–716.) Key words: Duchenne/Becker muscular dystrophy • gene deletion • muscle membrane

Introduction

Dystrophin, the 427 kD protein produced by the Duchenne muscular dystrophy/Becker muscular dystrophy (DMD/BMD) gene, shares many features with the cytoskeletal proteins spectrin and alpha-actinin. It has an extended spectrin-like central domain, and more globular amino- and carboxyl-terminal domains (1). Its location in muscle at the inner surface of the plasma membrane (2, 3), despite the lack of any transmembrane domain, suggests that dystrophin is associated with membrane proteins. Very likely candidates are the integral membrane sarcolemmal glycoproteins, characterized

by Campbell et al. (4, 5). However, the precise domain(s) of interaction remains speculative. It has been hypothesized that the tight membrane association is mediated by the cysteine-rich and/or COOH-terminal domains of dystrophin. This assumption was first based on indirect arguments, such as the very high degree of conservation at nucleotide and amino-acid levels of these domains (6), the correlation between the disease severity (Duchenne versus Becker), and dystrophin-domain alteration (7). It was further assessed by ultrastructural studies using a COOH-terminal antibody (25).

Here, we report the case of a 1-yr-old boy carrying a large deletion removing the distal part of the dystrophin gene beyond exon 49, and encompassing the glycerol kinase and congenital adrenal hypoplasia genes. In skeletal muscle we found a truncated dystrophin, that, although lacking the cysteine-rich and COOH-terminal domains, seems to be stable and to retain normal sarcolemmal localization.

Methods

Case. The proband A.B. is a male patient with muscular dystrophy, glycerol kinase deficiency, congenital adrenal hypoplasia, and poor psychomotor development. Diagnosis was made at birth because of adrenal failure. The histological and histochemical study of a muscle biopsy specimen taken at the age of 9 mo showed the characteristic features of muscular dystrophy: (a) numerous necrotic muscle fibers; (b) foci of regenerating fibers; (c) discrete type 1 fiber predominance; and (d) marked increase in collagen endomysial tissue. Full familial, clinical, and molecular details will be given elsewhere. PCR-multiplex analysis of peripheral blood DNA, to explore the muscle promoter, and 17 exons of the dystrophin gene (8, 9), showed that exons 50, 51, 52, and 60 were missing. The size of the deletion was further documented by Southern analysis that showed a terminal deletion of the dystrophin gene with a proximal breakpoint between exons 49 and 50. A junction fragment was detected on EcoRI and XmnI digests (Fig. 1). The distal breakpoint of the deletion mapped between C7 and L1 probes (data not shown).

Immunoblotting. Western blot analysis of muscle biopsy specimens from normal and patient A.B. was performed according to Nicholson et al. (10), using polyclonal (60 kd) (11) and monoclonal (Dy4/6D3) (10) antibodies directed against the central part of dystrophin, a monoclonal antibody (Dy10/12B2) directed against an epitope in the NH₂-terminal part of the protein within exons 10 to 12 (12), and a monoclonal antibody Dy8/6C5 directed against the 17 last amino acids (12).

Address correspondence and reprint requests to Dr. Dominique Récan, INSERM U129, CHU Cochin 24, rue du Faubourg Saint-Jacques 75014 Paris, France. Dr. Jamel Chelly's present address is Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK.

Received for publication 30 August 1991 and in revised form 8 November 1991.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/92/02/0712/05 \$2.00

Volume 89, February 1992, 712–716




Figure 1. Southern blot of genomic DNA digested by HindIII, XmnI, and EcoRI, and hybridized with the cDNA probe 8 (4). (Lane 1) patient A.B.'s mother; (Lane 2) patient A.B.; (lane 3) normal male control DNA. Hybridization pattern on patient A.B.'s DNA (lane 2) shows the absence of fragments containing exons 50–52 on HindIII digest, and a junction fragment corresponding to exon 49 on XmnI and EcoRI digests (arrow). Gene dosage and junction band on DNA of his mother (lane 1) indicate her carrier status.

Immunocytochemistry. The muscle biopsy specimens were immediately frozen in isopentane, cooled in liquid nitrogen, and stored at -80°C . Histochemical studies using conventional techniques and immunocytochemical characterization of dystrophin were performed in transverse cryostat sections. The immunodetection was performed on 4 to 6- μm sections by indirect immunofluorescence, using the above mentioned polyclonal and monoclonal antidystrophin antibodies, and revealed with corresponding fluorescein isothiocyanate-conjugated IgG (13). Sections were examined with a Leitz photomicroscope equipped with epifluorescence illumination.

Results and Discussion

From the physical map of the Xp21 region constructed by pulse field gel electrophoresis (14–16), we estimate that the deletion in patient A.B. encompasses at least 4,000 kb of genomic DNA, starting between exons 49 and 50, and ending between C7 and L1. The position of the distal breakpoint confirms the proximal position of C7 (16, 17), and indicates that the deletion eliminates the congenital adrenal hypoplasia and




Figure 2. Western blot of control human normal muscle (*N*) and patient muscle specimen (*P*) probed with (a) anti-dystrophin monoclonal antibody Dy4/6D3 (10); (b) anti-dystrophin monoclonal antibody Dy8/6C5 (12). *Dy*, dystrophin; *Dy**, truncated dystrophin; *Myo*, myosin.

glycerol kinase genes (17). In addition, it removes the sequences corresponding to part of the third hinge region, the five last repeats of the spectrin-like domain, and the whole cysteine-rich and COOH-terminal domains of the dystrophin protein (18). We thus expected that the deleted dystrophin gene would produce an unstable truncated dystrophin. Surprisingly, Western blot analysis of a muscle biopsy from the patient, using antibodies directed against the central part (60 kd) (11) and

(Dy4/6D3) (10), and against the NH₂-terminal part (Dy10/12B2) of dystrophin, showed the presence of a truncated dystrophin of about 270 kD, which was only slightly diminished in labeling intensity (about 60% of the normal dystrophin) (Fig. 2). In contrast, no signal was detected with Dy8/6C5, which recognizes the 17 last amino-acids of dystrophin (12).

Immunocytochemical analysis showed that there was no labeling with antibodies directed against the COOH-terminal deleted region (antibody Dy8/6C5). In contrast, with antibodies 60 kd and Dy10/12B2 there was an uniform labeling of the sarcolemma of the muscle fibers (Fig. 3). This labeling was less strong than in normal controls, but more intense than in most of Becker muscular dystrophy patients (Fig. 3).

The 270-kD band obtained with antibodies directed against dystrophin sequences upstream of exon 50 is consistent with the size of the DNA deletion, which suggests a protein product of 280 kD. It cannot be a proteolytic product of the autosomal (19) 420-kD dystrophin-related protein (20), since this protein is not recognized by the Dy10/12B2 monoclonal antibody (data not shown).

These data indicate that this patient produces a stable, truncated dystrophin, that, although devoid of the cysteine-rich and




Figure 3. Indirect immunofluorescence localization of dystrophin using anti-dystrophin monoclonal antibody DY10/12B2 (12) in unfixed cryostat transverse section of muscle fibers. (*Normal*) even distribution of dystrophin in the sarcolemma of all fibers. (*BMD*) marked diminution of the labeling of the sarcolemma in a Becker muscular dystrophy patient aged 29. (*DMD*) absence of dystrophin in a 6-yr-old Duchenne muscular dystrophy patient. (*Patient*) the labeling is strictly sarcolemmal and of intermediate intensity between normal and Becker muscular dystrophy. Magnification 175.

COOH-terminal domains, appears to be correctly located at the muscle cell sarcolemma. This unexpected result suggests that these domains are not essential for the sarcolemmal localization of dystrophin, and that interactions between other regions of the dystrophin molecule and proteins closely associated with the membrane must occur, as previously suggested by Cross et al. (21). Interestingly, the truncated dystrophin (deletion of exons 17 to 48) of the Becker patient reported by England et al. (22) is normally localized at the sarcolemma. In addition, deletions removing various parts of the dystrophin gene, somewhere between exon 1 and exon 53, and producing a Becker phenotype, have been reported (7, 23). Although these reports do not mention immunohistochemical analysis, one may infer that the truncated dystrophin detectable on Western blots (23) is attached *in vivo* to sarcolemma. Altogether, these results, combined with the data observed in patient A.B., suggest that the COOH-terminal domain, which seems to be attached to the membrane (24, 25), is not critical in membrane connection. Other more proximal domains of dystrophin might be involved, thus allowing some membrane binding if one of them is missing. In Fig. 4, we propose a speculative model, derived from the one recently presented by Ervasti et al. (24).

Another possibility is that the truncated dystrophin of patient A.B. has a new COOH-terminal end, deriving from the translation of an unknown sequence downstream of the deletion breakpoint. However, the size of the truncated dystrophin is not in favor of this hypothesis. The fact that the amount of truncated dystrophin is only slightly diminished suggests that the mRNA is stable, although it lacks the 3-kb-long, highly conserved untranslated sequence. The transcript is being currently analyzed in order to define precisely the position of the stop codon, and the sequence beyond it.

The propositus is now 18 mo old, and it is difficult to anticipate what will be the clinical evolution of the muscle disease, i.e., towards a Duchenne or a Becker phenotype. Although traces of truncated dystrophin may be present in Duchenne

patients (26), the presence of a significant amount of dystrophin is, in principle, indicative of a Becker-type disease (25). Indeed, we recently found substantial amounts of dystrophin in muscle samples taken in infants who were diagnosed at birth several years ago, on the basis of high plasma creatine-kinase activity, and who had ultimately developed a Becker phenotype (unpublished data). One could thus anticipate that the patient reported here should have a mild phenotype. However, it remains possible that its truncated but stable dystrophin is nonfunctional, and that a more severe disease will develop. No correlation can be made with previously reported cases associating myopathy, glycerol kinase deficiency, adrenal insufficiency, and a deletion starting in the distal portion of the dystrophin gene (28, 29), since the status and localization of dystrophin in these patients have not yet been reported.

The distal part of dystrophin is highly conserved, both at the amino acid and at the nucleotide level (3). This is thought to reflect stringent requirements for attachment to the membrane through interacting proteins. This explanation may now be questioned, since it appears that membrane binding can be ensured by other domains of dystrophin. One can hypothesize that the high degree of conservation of this portion of the gene is due rather to its involvement in the production of other essential proteins, such as the 80-kD protein (Chelly et al., manuscript in preparation) corresponding to the recently described 6.5-kb mRNA that is transcribed by the distal part of the dystrophin gene (30).

Acknowledgments

We thank E. Hoffman and T. Khurana for generous supply of 60-kD anti-dystrophin and anti-dystrophin related protein antibodies, and M. Cullen and H. Gilgenkrantz for fruitful discussion.

This work was supported in part by the Association Française contre les Myopathies, the Muscular Dystrophy Group of Great Britain, and the Wellcome Trust.




Figure 4. Speculative model of dystrophin, combining the model of Ervasti et al. (24) and our findings, showing the truncated dystrophin still attached to the membrane by its NH₂-terminal end in patient A.B. In this model, additional possible interaction between internal parts, such as hinge regions and membrane, is not represented.

Note added in proof. After submission of our manuscript, a paper by Eric P. Hoffman et al. (Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of Duchenne muscular dystrophy) describing similar findings appeared in *Annals of Neurology* (1991. 30:605–610).

References

1. Koenig, M., A. Monaco, and L. Kunkel. 1988. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell*. 53:219–228.
2. Arahata, K., S. Ishiura, T. Ishiguro, T. Tsukahara, Y. Suhara, C. Eguchi, T. Ishihara, I. Nonaka, E. Ozawa, and H. Sugita. 1988. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. *Nature (Lond.)*. 333:861–863.
3. Zubrzycka-Gaarn, E. E., D. E. Bulman, G. Karpati, H. M. Burghes, B. Belfall, H. J. Klamut, J. Talbot, R. S. Hodges, P. N. Ray, and R. G. Worton. 1988. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. *Nature (Lond.)*. 333:466–469.
4. Campbell, K. and S. Kahl. 1989. Association of dystrophin and an integral membrane glycoprotein. *Nature (Lond.)*. 338:259–262.
5. Ervasti, J., K. Ohlendieck, S. Kahl, M. Gaver, and K. Campbell. 1990. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. *Nature (Lond.)*. 345:315–319.
6. Lemaire, C., R. Heilig, and J. Mandel. 1988. The chicken dystrophin cDNA: striking conservation of the C-terminal coding and 3' untranslated regions between man and chicken. *EMBO (Eur. Mol. Biol. Organ.) J.* 7:4157–4162.
7. Koenig, M., A. Beggs, M. Moyer, S. Scherpf, K. Heindrichs, T. Bettecken, G. Meng, C. Müller, M. Lindlöf, H. Kääriäinen, et al. 1989. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. *Am. J. Hum. Genet.* 45:498–506.
8. Chamberlain, J. S., R. A. Gibbs, J. E. Ranier, P. N. Nguyen, and C. T. Caskey. 1988. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. *Nucleic Acids Res.* 16:1141–1156.
9. Beggs, A., M. Koenig, F. Boyce, and L. Kunkel. 1990. Detection of 98% of DMD/BMD deletions by PCR. *Hum. Genet.* 86:45–48.
10. Nicholson, L., K. Davison, G. Falkous, C. Harwood, E. O'Donnell, C. Slater, and J. Harris. 1989. Dystrophin in skeletal muscle I. Western blot analysis using a monoclonal antibody. *J. Neurol. Sci.* 94:125–136.
11. Hoffman, E. P., J. Brown R. H., and L. M. Kunkel. 1987. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell*. 51:919–928.
12. Nicholson, L. V. B., M. A. Johnson, K. Davison, E. O'Donnell, G. Falkous, M. Barron, and J. Harris. 1991. Dystrophin or a "related protein" in Duchenne muscular dystrophy? *Acta Neurol. Scand.* In press.
13. Fardeau, M., F. Tomé, H. Collin, N. Augier, F. Pons, J. Léger, and J. Léger. 1990. Présence d'une protéine de type dystrophine au niveau de la jonction neuromusculaire dans la dystrophie musculaire de Duchenne et la souris mutante "mdx". *C. R. Acad. Sci. Paris.* 311:197–204.
14. van Ommen, G. J. B., C. Bertelson, H. B. Ginjaar, J. T. Den Dunnen, E. Bakker, J. Chelly, M. Matton, A. J. Van Essen, J. Bartley, L. M. Kunkel, et al. 1987. Long-range genomic map of the Duchenne muscular dystrophy gene: isolation and use of J66 (DXS268), a distal intragenic marker. *Genomics.* 1:329–336.
15. Burmeister, M., A. P. Monaco, E. F. Gillard, G. J. B. van Ommen, N. A. Affara, M. A. Ferguson-Smith, L. M. Kunkel, and H. Lehrach. 1988. A 10 megabase physical map of human Xp21, including the Duchenne muscular dystrophy gene. *Genomics.* 2:189–202.
16. Love, D., J. Bloomfield, S. Kenwright, J. Yates and K. Davies. 1990. Physical mapping distal to the DMD locus. *Genomics.* 8:106–112.
17. Towbin, J. A., J. S. Chamberlain, D. Wu, D. A. M. Pillers, W. K. Seltzer, and E. R. B. McCabe. 1990. DXS28(C7) maps centromeric to DXS68 (L1-4) and DXS67 (B24) by deletion analysis. *Genomics.* 7:442–444.
18. Koenig, M., and L. Kunkel. 1990. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. *J. Biol. Chem.* 265:4560–4566.
19. Love, D., D. Hill, G. Dickson, N. Spurr, B. Blyth, R. Marssden, F. Walsh, Y. Edwards, and K. Davies. 1989. An autosomal transcript in skeletal muscle with homology to dystrophin. *Nature (Lond.)*. 339:55–58.
20. Khurana, T., E. Hoffman, and L. Kunkel. 1990. Identification of a chromosome 6-encoded dystrophin related protein. *J. Biol. Chem.* 265:16717–16720.
21. Cross, R., M. Stewart, and J. Kendrick-Jones. 1990. Structural predictions for the central domain of dystrophin. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 262:87–92.
22. England, S., L. Nicholson, M. Johnson, S. Forrest, D. Love, E. Zubrzycka-Gaarn, D. Bulman, J. Harris, and K. Davies. 1990. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. *Nature (Lond.)*. 343:180–182.
23. Beggs, A., E. Hoffmann, J. Snyder, K. Arahata, L. Specht, F. Shapiro, C. Angelini, H. Sugita, and L. Kunkel. 1991. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. *Am. J. Hum. Genet.* 49:54–67.
24. Ervasti, J., and K. Campbell. 1991. Membrane organization of the dystrophin-glycoprotein complex. *Cell*. 66:1121–1131.
25. Cullen, M., J. Walsh, L. Nicholson, J. Harris, E. Zubrzycka-Gaarn, P. Ray, and R. Worton. 1991. Immunogold labeling of dystrophin in human muscle, using an antibody to the last 17 amino acids of the C-terminus. *Neuromuscular Disorders.* 1:113–119.
26. Bulman, D., E. Murphy, E. Zubrzycka-Gaarn, R. Worton, and P. Ray. 1991. Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin. *Am. J. Hum. Genet.* 48:295–304.
27. Hoffman, E., L. Kunkel, C. Angelini, A. Clarke, M. Johnson, and J. Harris. 1989. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. *Neurology.* 39:1011–1017.
28. Darras, B. T., and U. Francke. 1988. Myopathy in complex glycerolkinase deficiency patients is due to 3' deletions of the dystrophin gene. *Am. J. Hum. Genet.* 43:126–130.
29. McCabe, E. R. B., J. Towbin, J. Chamberlain, L. Baumbach, J. Witkowski, G. J. B. van Ommen, M. Koenig, L. M. Kunkel, and W. K. Seltzer. 1989. Complementary DNA probes for the Duchenne muscular dystrophy locus demonstrate a previously undetectable deletion in a patient with dystrophic myopathy, glycerol kinase deficiency, and congenital adrenal hypoplasia. *J. Clin. Invest.* 83:95–99.
30. Bar, S., E. Barnea, Z. Levy, S. Neuman, D. Yaffé, and U. Nudel. 1990. A novel product of the Duchenne muscular dystrophy gene which greatly differs from the known isoforms in its structure and tissue distribution. *Biochem. J.* 272:557–560.